机构:[1]Department of Mammary Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China[2]Department of Tumor 2 Families, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China[3]Department of Blood Transfusion, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China医技片输血科云南省第一人民医院[4]Department of Anesthesiology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China[5]Department of Kunming Maternal and Child Health Service Centre, Kunming City Maternal and Child Health Hospital, Kunming, China
Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer, and chemoresistance is the major determinant of TNBC treatment failure. This study explores the molecular mechanism of TNBC chemoresistance. The Cancer Genome Atlas, breast cancer integrative platform, and GEPIA databases were used to analyze the expression and correlation of YTHDF1 and seven in absentia homology 2 (SIAH2) in breast cancer. Knockdown of YTHDF1 and SIAH2, or overexpression of SIAH2 in vitro and in vivo, was conducted to evaluate the impact of changes in YTHDF1 and SIAH2 expression on TNBC cell proliferation, apoptosis, stemness, drug resistance, and Hippo pathway gene expression. YTHDF1 and SIAH2 were highly expressed in breast cancer patients and TNBC cells. Knockdown of YTHDF1 and SIAH2 significantly inhibited proliferation and stemness and promoted apoptosis and chemosensitivity of TNBC cells. Mechanistically, the knockdown of YTHDF1 inhibited the expression of SIAH2, thereby downregulating the Hippo pathway, which inhibited proliferation and stemness and promoted apoptosis and chemosensitivity of TNBC cells. The current findings revealed the regulatory mechanism of YTHDF1 in TNBC and clarified the role of the YTHDF1/SIAH2 axis in TNBC drug resistance and stemness. This could provide new insights into the vital role of targeting YTHDF1/SIAH2 to suppress drug resistance and stemness in TNBC cells.
基金:
Yunnan Fundamental Research Projects,
Grant/Award Numbers: 202201AU070007,
202201AY070001‐147,
202201AY070001‐146
第一作者机构:[1]Department of Mammary Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Mammary Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, China[*1]Department of Mammary Surgery I, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), No. 519, Kunzhou Rd., Kunming 650118, China
推荐引用方式(GB/T 7714):
Wu Anhao,Wang Xi,Zhang Fang,et al.YTHDF1 enhances stemness and chemoresistance in triple-negative breast cancer cells by upregulating SIAH2[J].MOLECULAR CARCINOGENESIS.2024,63(3):417-429.doi:10.1002/mc.23661.
APA:
Wu, Anhao,Wang, Xi,Zhang, Fang,Yang, Xin,Quan, Yuhang...&Wang, Maohua.(2024).YTHDF1 enhances stemness and chemoresistance in triple-negative breast cancer cells by upregulating SIAH2.MOLECULAR CARCINOGENESIS,63,(3)
MLA:
Wu, Anhao,et al."YTHDF1 enhances stemness and chemoresistance in triple-negative breast cancer cells by upregulating SIAH2".MOLECULAR CARCINOGENESIS 63..3(2024):417-429